Abstract
Protein-protein interactions (PPIs) are becoming highly attractive targets for drug discovery. Motivated by the rapid accumulation of PPI data in public database and the success stories concerning the targeting of PPIs, a machine-learning method based on sequence and structure properties was developed to access the druggability of PPIs. Here, a comprehensive non-redundant set of 34 druggable and 122 less druggable PPIs were firstly presented from the perspective of pockets. When tested by outer 5-fold cross-validation, the most representative model in discriminating the druggable PPIs from the less-druggable ones yielded an average accuracy of 88.24% (sensitivity of 82.38% and specificity of 92.00%). Moreover, a promising result was also obtained for the independent test set. Compared to other methods, the method gives a comparative performance, which is most likely due to the construction of a training set that encompasses less druggable PPIs and also the information of active pockets that have evolved to bind a natural ligand.
Keywords: Active pockets, druggability, protein-protein interactions, sequence features, structure features, support vector machine.
Current Pharmaceutical Design
Title:Predicting the Druggability of Protein-Protein Interactions Based on Sequence and Structure Features of Active Pockets
Volume: 21 Issue: 21
Author(s): Xu Dai, RunYu Jing, Yanzhi Guo, YongCheng Dong, YueLong Wang, Yuan Liu, XueMei Pu and Menglong Li
Affiliation:
Keywords: Active pockets, druggability, protein-protein interactions, sequence features, structure features, support vector machine.
Abstract: Protein-protein interactions (PPIs) are becoming highly attractive targets for drug discovery. Motivated by the rapid accumulation of PPI data in public database and the success stories concerning the targeting of PPIs, a machine-learning method based on sequence and structure properties was developed to access the druggability of PPIs. Here, a comprehensive non-redundant set of 34 druggable and 122 less druggable PPIs were firstly presented from the perspective of pockets. When tested by outer 5-fold cross-validation, the most representative model in discriminating the druggable PPIs from the less-druggable ones yielded an average accuracy of 88.24% (sensitivity of 82.38% and specificity of 92.00%). Moreover, a promising result was also obtained for the independent test set. Compared to other methods, the method gives a comparative performance, which is most likely due to the construction of a training set that encompasses less druggable PPIs and also the information of active pockets that have evolved to bind a natural ligand.
Export Options
About this article
Cite this article as:
Dai Xu, Jing RunYu, Guo Yanzhi, Dong YongCheng, Wang YueLong, Liu Yuan, Pu XueMei and Li Menglong, Predicting the Druggability of Protein-Protein Interactions Based on Sequence and Structure Features of Active Pockets, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150309143106
DOI https://dx.doi.org/10.2174/1381612821666150309143106 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Novel Drug Therapies for Fertility Preservation in Men Undergoing Chemotherapy: Clinical Relevance of Protector Agents
Current Medicinal Chemistry Interactions of Chemicals and Metal Ions with Proteins and Role for Immune Responses
Mini-Reviews in Medicinal Chemistry Targeted Therapies in Bone Sarcomas
Current Cancer Drug Targets The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice
Current Molecular Medicine Nanosized Tamoxifen-Porphyrin-Glucose [TPG] Conjugate: Novel Selective Anti-breast-cancer Agent, Synthesis and In Vitro Evaluations
Medicinal Chemistry Anti-Angiogenic and Anti-Inflammatory Effects of Statins: Relevance to Anti-Cancer Therapy
Current Cancer Drug Targets Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Metallothioneins and Cancer
Current Protein & Peptide Science The Gene Expression Profiles of Medulloblastoma Cell Lines Resistant to Preactivated Cyclophosphamide
Current Cancer Drug Targets Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry Biosystems Engineering of Prokaryotes with Tumor-Killing Capacities
Current Pharmaceutical Design Transcription Factors in Heart: Promising Therapeutic Targets in Cardiac Hypertrophy
Current Cardiology Reviews Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Management of Vaginal Cancer
Reviews on Recent Clinical Trials